Pegfilgrastim OBI device use for neutropenia prevention: a scoping review
Authors:
- Vivian Do Prado MartinsVMVivian Do Prado Martins
- Karina Dal Sasso MendesKMKarina Dal Sasso Mendes
- Bruna Nogueira dos SantosBSBruna Nogueira dos Santos
- Bruno Andraus FilardiBFBruno Andraus Filardi
- Letícia Genova VieiraLetícia Genova Vieira
- Renata Cristina de Campos Pereira SilveiraRSRenata Cristina de Campos Pereira Silveira
Open Access
- 9 August 2023
- journal article
- review article
- Published by Acta Paulista de Enfermagem in Acta Paulista de Enfermagem
- Vol. 36
Abstract
Objective: To map the health care of Pegfilgrastim On-body Injector in neutropenia prevention in adults with cancer in home care after outpatient chemotherapy. Methods: This is a scoping review based on the JBI methodology. Only studies with adults with cancer undergoing outpatient chemotherapy were included. The search was carried out in the Cochrane, CINAHL, EMBASE, LILACS, PubMed, Scopus, LIVIVO and Web of Science databases, in addition to gray literature ProQuest, SciELO, Database in Nursing, Google Scholar, Open Grey, drug leaflet and websites. The searches in the references of selected studies were exhausted. All identified studies were exported to the EndNote reference manager for organization and removal of duplicates. The Rayyan web application was used for evidence selection. The studies were selected by pairs independently, with conflicts resolved by a third researcher. Results: A total of 10 articles were included, whose results were subdivided into categories: patient compliance, health team opinion, patient workload in cancer treatment and device use in clinical practice. The device has few flaws and was accepted by health care teams and patients in most studies. Conclusion: The main health care for Pegfilgrastim On-body Injector use is related to the skin preparation technique where the device will be applied, in addition to device preparation and administration. Moreover, the importance of assessing the knowledge of patients and their family about the device is highlighted, providing all the necessary guidelines, verbally and in writing, clearly and objectively, and validating this information, making sure that patients have understood all of them and are safe.Keywords
Funding Information
- Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (001)
This publication has 15 references indexed in Scilit:
- A prospective cohort study to evaluate the incidence of febrile neutropenia in patients receiving pegfilgrastim on-body injector versus other options for prophylaxis of febrile neutropenia: breast cancer subgroup analysisSupportive Care in Cancer, 2022
- Patient, nurse, and physician preferences: final results of the CONVENIENCE study evaluating pegfilgrastim prophylaxis via pre-filled syringe or on-body injector in cancer patientsSupportive Care in Cancer, 2021
- Development and content validation of the Satisfaction and Experience Questionnaire for Granulocyte Colony-Stimulating Factor (SEQ-G-CSF)Journal of Patient-Reported Outcomes, 2021
- Measures of Treatment Workload for Patients With Breast CancerJCO Clinical Cancer Informatics, 2019
- Retrospective Analysis of Clinical Outcomes Associated With the Use of Pegfilgrastim On-body Injector in Patients Receiving Chemotherapy Requiring Granulocyte Colony-Stimulating Factor SupportHospital Pharmacy, 2019
- Risk factors for neutropenia and febrile neutropenia following prophylactic pegfilgrastimAsia-Pacific Journal of Clinical Oncology, 2019
- Haematological toxicities with immunotherapy in patients with cancer: a systematic review and meta-analysisEuropean Journal of Cancer, 2018
- On-Body Injector: An Administration Device for PegfilgrastimClinical Journal of Oncology Nursing, 2017
- Rayyan—a web and mobile app for systematic reviewsSystematic Reviews, 2016
- Comparison of pharmacokinetics and safety of pegfilgrastim administered by two delivery methods: on-body injector and manual injection with a prefilled syringeCancer Chemotherapy and Pharmacology, 2015